Tablets for chronic heart failure with low pumping strength
Part of Heart & circulation clinical trials.
This Phase 3 study tests whether S086 tablets can improve treatment for people with chronic heart failure where the heart pumps weakly. You may be eligible if your heart failure symptoms are moderate to severe and your condition is stable on current medicines, but not if you’ve recently had certain heart events or can’t take related blood-pressure/heart drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic heart failure with NYHA class II to IV symptoms (moderate to severe).
- Your heart’s pumping strength is reduced (left ventricular ejection fraction 40% or less).
- Your BNP blood test is high, and you were diagnosed with these criteria at least 1 time.
- Your heart failure medicines have been on a steady dose for at least 4 weeks before screening.
- You must be willing to join the study and sign informed consent.
- You must not have had S086-related blood-pressure heart medicine restrictions (see questions below).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood-pressure and heart-failure medicines: sacubitril/valsartan versus ramipril, to see which improves heart pumping and heart structure over time. It’s aimed at people with ischemic (blocked-artery) heart failure with mid-range ejection fraction and ongoing symptoms.
This trial tests a medicine called sacubitril-valsartan for people in rural Tanzania with heart failure and reduced pumping strength. It aims to see if switching to this drug can improve symptoms and outcomes.
This study tests whether a medication called sacubitril/valsartan can improve the heart's ability to relax and fill with blood (diastolic function) in people with heart failure with reduced ejection fraction. It may help improve your heart function and overall well-being.
This study tests a new medicine called NT-88, which may help improve heart function in people with mild heart failure. It focuses on those with a slightly reduced pumping ability (LVEF 41-49%) and aims to see if the drug is safe and helpful.
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
This trial tests whether a combination of two blood pressure drugs (sacubitril/valsartan) is better than one drug alone (valsartan) at improving heart function in people with high blood pressure. It may help reduce strain on the heart's upper chambers.
Hear when a new Chronic Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.